1 a diagnostic criterion and can be applied to
neonatal screening.
2 trategies for sickle cell disease, including
neonatal screening.
3 ls to assess the effectiveness and safety of
neonatal screening and early treatment.
4 blood spot samples obtained from the Danish
Neonatal Screening Biobank and genotyped using the Illum
5 d individuals were retrieved from the Danish
Neonatal Screening Biobank.
6 zation, and DNA was obtained from the Danish
Neonatal Screening Biobank.
7 DNA was obtained from the Danish
Neonatal Screening Biobank.
8 Neonatal screening for CAH and gene-specific prenatal di
9 We assessed
neonatal screening for CAH from January 1, 1986, through
10 As a result of such screening efforts,
neonatal screening for CAH has proven to be highly relia
11 nt reports have questioned the rationale for
neonatal screening for congenital adrenal hyperplasia (C
12 Consideration must be given to universal
neonatal screening for cytomegalovirus to facilitate ear
13 We reviewed the results of
neonatal screening for homocystinuria over a period of 3
14 Neonatal screening for SCID would significantly improve
15 We used data on CHT from the national
neonatal screening lab of Israel, and exposure data from
16 These include
neonatal screening of immunodeficiencies and asthma biom
17 patients with cystic fibrosis identified by
neonatal screening or by standard diagnostic methods.
18 In CF patients diagnosed through
neonatal screening,
P aeruginosa pulmonary infections oc
19 successfully transitioned into the official
neonatal screening program in Southern Belgium.
20 e facilitated the introduction of nationwide
neonatal screening programmes for a large number of meta
21 ren necessitates implementation of universal
neonatal screening programmes for hearing impairment.
22 Neonatal screening programmes, based on clinical screeni
23 s, stem cell transplantation facilities, and
neonatal screening programs.
24 a detected in tandem mass spectrometry-based
neonatal screening programs.
25 The Wisconsin CF
Neonatal Screening Project is a longitudinal investigati
26 n and treatment protocol of the Wisconsin CF
Neonatal Screening Project.
27 Although CF
neonatal screening provides a potential opportunity for
28 Neonatal screening provides the opportunity to prevent m
29 ic categories: meconium ileus (MI), prenatal/
neonatal screening (
SCREEN), positive family history (FH
30 or blood methionine of 1 mg per deciliter in
neonatal screening tests for homocystinuria should ident
31 infection as well as the lack of large-scale
neonatal screening tools.
32 lasma and DBS, as well as urine and DUS made
neonatal screening using DBS and DUS possible.